
    
      A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study
      to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50 mg or 150 mg) for Three
      Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron
      Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge
      Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and
      Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an
      Increased Emetogenic Risk
    
  